GRT-R902

GRT-R902 is a self-amplifying mRNA (samRNA)-based, personalized cancer vaccine developed as part of the GRANITE immunotherapy regimen. It is designed to deliver patient-specific tumor neoantigens identified through sequencing and bioinformatic prediction, with the goal of stimulating a robust T-cell immune response—particularly CD8+ cytotoxic T cells—against mutation-derived tumor-specific antigens. GRT-R902 is used in combination with an adenoviral vector (GRT-C901) as a heterologous prime/boost strategy to enhance immunogenicity. The vaccine regimen has been studied primarily in metastatic microsatellite stable colorectal cancer (MSS-CRC), but also in other solid tumors, often alongside immune checkpoint inhibitors such as ipilimumab and atezolizumab[1][6][7][9].